Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Abstract

As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594 ; EudraCT number, 2014-004944-37 .).

Keywords

Affiliated Institutions

• The Netherlands Cancer Institute NL
• Royal Marsden Hospital GB
• University Hospital Heidelberg DE
• Assistance Publique Hôpitaux de Marseille FR
• Ospedale Papa Giovanni XXIII IT
• University Hospital and Clinics US
• Aix-Marseille Université FR
• Hospital Universitari de Vic ES
• Merck & Co., Inc., Rahway, NJ, USA (United States) US
• Russian Cancer Research Center NN Blokhin RU
• Hospices Civils de Lyon FR
• The University of Western Australia AU
• Melanoma Institute Australia AU
• Edith Cowan University AU
• Blacktown & Mount Druitt Hospital AU
• The Christie NHS Foundation Trust GB
• Fiona Stanley Hospital AU
• Peter MacCallum Cancer Centre AU
• University Medical Center US
• The Alfred Hospital AU
• The University of Queensland AU
• Centre de Recherche en Cancérologie de Lyon FR
• Deutschen Konsortium für Translationale Krebsforschung
• Institut Gustave Roussy FR
• The Maria Sklodowska-Curie National Research Institute of Oncology PL
• Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" IT
• Centre Hospitalier de l’Université de Montréal CA
• Amsterdam UMC Location Vrije Universiteit Amsterdam NL
• Cancer Institute (WIA) IN
• Hôpital de la Timone FR
• Royal North Shore Hospital AU
• The University of Sydney AU
• Radboud University Medical Center NL
• Washington University in St. Louis US
• European Organisation for Research and Treatment of Cancer BE
• Heidelberg University DE
• Medizinische Hochschule Hannover DE
• Radboud University Nijmegen NL

Related Publications